182 related articles for article (PubMed ID: 22847606)
1. Glucose transporter 1 (GLUT1) of anaerobic glycolysis as predictive and prognostic values in neoadjuvant chemoradiotherapy and laparoscopic surgery for locally advanced rectal cancer.
Shim BY; Jung JH; Lee KM; Kim HJ; Hong SH; Kim SH; Sun DS; Cho HM
Int J Colorectal Dis; 2013 Mar; 28(3):375-83. PubMed ID: 22847606
[TBL] [Abstract][Full Text] [Related]
2. GRP78 Protein Expression as Prognostic Values in Neoadjuvant Chemoradiotherapy and Laparoscopic Surgery for Locally Advanced Rectal Cancer.
Lee HY; Jung JH; Cho HM; Kim SH; Lee KM; Kim HJ; Lee JH; Shim BY
Cancer Res Treat; 2015 Oct; 47(4):804-12. PubMed ID: 25687871
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Okugawa Y; Fujikawa H; Matsushita K; Uchida K; Inoue Y; Kusunoki M
Surg Today; 2012 May; 42(5):460-9. PubMed ID: 22072148
[TBL] [Abstract][Full Text] [Related]
4. [Hypoxia-inducible factor-1α and CD133 predicts pathological complete response and survival for locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy].
Cai C; Wang J; Zhong Z; Dai Z; Wang Q; Dong W; Shi H; Liu Q; DU J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2017 Jan; 46(1):36-43. PubMed ID: 28436629
[TBL] [Abstract][Full Text] [Related]
5. Expression of hypoxia-inducible factor 1α predicts clinical outcome after preoperative hyperthermo-chemoradiotherapy for locally advanced rectal cancer.
Shioya M; Takahashi T; Ishikawa H; Sakurai H; Ebara T; Suzuki Y; Saitoh J; Ohno T; Asao T; Kuwano H; Nakano T
J Radiat Res; 2011; 52(6):821-7. PubMed ID: 22104271
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-related proteins in patients with rectal cancer undergoing neoadjuvant combined modality therapy.
Lee-Kong SA; Ruby JA; Chessin DB; Pucciarelli S; Shia J; Riedel ER; Nitti D; Guillem JG
Dis Colon Rectum; 2012 Sep; 55(9):990-5. PubMed ID: 22874607
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
9. Thymidine phosphorylase and hypoxia-inducible factor 1-α expression in clinical stage II/III rectal cancer: association with response to neoadjuvant chemoradiation therapy and prognosis.
Lin S; Lai H; Qin Y; Chen J; Lin Y
Int J Clin Exp Pathol; 2015; 8(9):10680-8. PubMed ID: 26617778
[TBL] [Abstract][Full Text] [Related]
10. The potential predictive value of tumor budding for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
Jäger T; Neureiter D; Fallaha M; Schredl P; Kiesslich T; Urbas R; Klieser E; Holzinger J; Sedlmayer F; Emmanuel K; Dinnewitzer A
Strahlenther Onkol; 2018 Nov; 194(11):991-1006. PubMed ID: 30069738
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
[TBL] [Abstract][Full Text] [Related]
12. Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
Arredondo J; Baixauli J; Beorlegui C; Arbea L; Rodríguez J; Sola JJ; Chopitea A; Hernández-Lizoáin JL
Dis Colon Rectum; 2013 Apr; 56(4):416-21. PubMed ID: 23478608
[TBL] [Abstract][Full Text] [Related]
13. Expression of hypoxia-inducible factor 1α, glucose transporter 1, and hexokinase 2 in primary central nervous system lymphoma and the correlation with the biological behaviors.
Shen N; Wang Y; Sun X; Bai X; He J; Cui Q; Qian J; Zhu H; Chen Y; Xing R; Liu Q; Wu Y; Li J; Lai W; Sun S; Ji N; Liu Y
Brain Behav; 2020 Aug; 10(8):e01718. PubMed ID: 32533646
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of tumour regression grade after neoadjuvant chemoradiotherapy for a cohort of patients with locally advanced rectal cancer: an 8-year retrospective single-institutional study.
Xu L; Cai S; Xiao T; Chen Y; Qiu H; Wu B; Lin G; Sun X; Lu J; Zhou W; Xiao Y
Colorectal Dis; 2017 Jul; 19(7):O263-O271. PubMed ID: 28603932
[TBL] [Abstract][Full Text] [Related]
15. Glucose transporter 1 (GLUT1) and its emerging role as a significant prognostic marker in systemic malignancies.
Kapoor S
Int J Colorectal Dis; 2013 Sep; 28(9):1317-8. PubMed ID: 23149615
[No Abstract] [Full Text] [Related]
16. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Hofheinz RD; Wenz F; Post S; Matzdorff A; Laechelt S; Hartmann JT; Müller L; Link H; Moehler M; Kettner E; Fritz E; Hieber U; Lindemann HW; Grunewald M; Kremers S; Constantin C; Hipp M; Hartung G; Gencer D; Kienle P; Burkholder I; Hochhaus A
Lancet Oncol; 2012 Jun; 13(6):579-88. PubMed ID: 22503032
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy.
Wen B; Zhang L; Wang C; Huang R; Peng H; Zhang T; Dong J; Xiao W; Zeng Z; Liu M; Gao Y
Radiat Oncol; 2015 Jun; 10():124. PubMed ID: 26040453
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of treatment response and tissue necrosis as prognostic indicators following neoadjuvant chemoradiotherapy in rectal cancer patients.
Jung JH; An HJ; Kim HJ; Lee J; Lee KM; Kim SH; Cho HM; Shim BY
Korean J Intern Med; 2016 Jan; 31(1):134-44. PubMed ID: 26767867
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of stromal CD26 expression in rectal cancer after chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
Int J Clin Oncol; 2016 Apr; 21(2):350-358. PubMed ID: 26370256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
